1. Home
  2. NKX vs SLN Comparison

NKX vs SLN Comparison

Compare NKX & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California AMT-Free Quality Municipal Income Fund

NKX

Nuveen California AMT-Free Quality Municipal Income Fund

HOLD

Current Price

$11.95

Market Cap

664.8M

Sector

Finance

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$14.82

Market Cap

678.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKX
SLN
Founded
2002
1994
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
664.8M
678.0M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
NKX
SLN
Price
$11.95
$14.82
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$42.60
AVG Volume (30 Days)
140.8K
1.5M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
4.37%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$559,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.68
$4.19
52 Week High
$13.20
$17.58

Technical Indicators

Market Signals
Indicator
NKX
SLN
Relative Strength Index (RSI) 33.64 64.91
Support Level $11.68 $13.01
Resistance Level $12.49 $17.58
Average True Range (ATR) 0.10 0.68
MACD -0.02 -0.09
Stochastic Oscillator 2.12 96.32

Price Performance

Historical Comparison
NKX
SLN

About NKX Nuveen California AMT-Free Quality Municipal Income Fund

Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: